DCPH Live signals | Maximize Profits with Getagraph.com

SELL 100927 min ago

@ $14.50

Issued: 13 Feb 2024 @ 15:32

Return: 1.17%

Previous signal: Feb 13 - 15:13

Previous signal: Buy

Return: 1.40 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Stats
Today's Volume	414 272
Average Volume	515 138
Market Cap	1.19B
EPS	$0 ( 2024-02-06 )
Next earnings date	( $-0.550 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.41
ATR14	$0.0180 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-15	Sherman Matthew L	Buy	17 275	Common Stock
2024-02-16	Sherman Matthew L	Sell	2 615	Common Stock
2024-02-15	Sherman Matthew L	Buy	69 100	Stock Option (Right to Buy)
2024-02-15	Kelly Thomas Patrick	Buy	17 275	Common Stock
2024-02-16	Kelly Thomas Patrick	Sell	3 010	Common Stock

INSIDER POWER
31.79
Last 99 transactions
Buy: 6 983 334 \| Sell: 3 513 431

Volume Correlation

Long: -0.36 (neutral)

Short: -0.91 (very strong negative)

Signal:(22.633) Possible Trading Opportunity Present (swing)

Deciphera Pharmaceuticals Correlation

10 Most Positive Correlations
BNIXU	0.869
HOTH	0.83
EVOJ	0.824
ACXP	0.801

10 Most Negative Correlations
CACG	-0.829
TSLA	-0.824
BUG	-0.807
GFS	-0.803

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Deciphera Pharmaceuticals Correlation - Currency/Commodity

-0.24
( neutral )

0.49
( neutral )

0.00
( neutral )

-0.26
( neutral )

0.00
( neutral )

-0.65
( weak negative )

Deciphera Pharmaceuticals Financials

Annual	2023
Revenue:	$163.36M
Gross Profit:	$159.62M (97.72 %)
EPS:	$-2.29

Q4	2023
Revenue:	$48.29M
Gross Profit:	$46.51M (96.30 %)
EPS:	$-0.540

Q3	2023
Revenue:	$43.31M
Gross Profit:	$42.03M (97.03 %)
EPS:	$-0.580

Q2	2023
Revenue:	$38.30M
Gross Profit:	$38.13M (99.55 %)
EPS:	$-0.570

Financial Reports:

No articles found.

Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.